Orthocell, Ltd.
Orthocell is dedicated to developing regenerative medicine therapies that support the body's own repair mechanisms. They focus on innovative solutions for nerve repair, tissue regeneration, and complex injuries, with a strong emphasis on commercializing life-changing products. The company is ASX-listed, with a history of high growth potential and a global presence, including regulatory approvals and a broad distributor network. Their mission is to redefine nerve repair and advance regenerative medicine to improve patient outcomes worldwide.
Industries
Nr. of Employees
small (1-50)
Orthocell, Ltd.
Melville, Western Australia, Australia, Oceania
Patents
Products
Remplir
Implantable nerve repair device designed to support peripheral nerve regeneration and improve functional recovery compared to standard suture techniques.
Remplir
Implantable nerve repair device designed to support peripheral nerve regeneration and improve functional recovery compared to standard suture techniques.
Services
Partnerships with healthcare professionals, provision of surgical support and professional education to facilitate adoption of regenerative-medicine devices.
Establishment and coordination of regional distributor networks and market rollouts for medical devices.
Partnerships with healthcare professionals, provision of surgical support and professional education to facilitate adoption of regenerative-medicine devices.
Establishment and coordination of regional distributor networks and market rollouts for medical devices.
Expertise Areas
- Regenerative medicine
- Peripheral nerve repair and reconstruction
- Biomaterial scaffold engineering
- Medical device development and commercialization
Key Technologies
- Collagen-based scaffold biomaterials
- Implantable nerve repair conduits
- Tissue-engineering scaffold design
- Clinical study methodologies for device evaluation
News & Updates
Orthocell has reached a critical milestone in the commercialization of Remplir™ in the US$1.6 Billion US market, recording its first sales revenue from the nerve repair product in the US.
Orthocell has released its Quarterly Report for the period ended 30 June 2025.
Orthocell announced a record quarterly revenue of $2.73 million for the June quarter, marking the fifth consecutive quarter of record revenue growth.
Orthocell recorded the first use of Remplir™ in the US, an important step in establishing surgical experience and knowledge of the product.
Orthocell announced interim results from a study showing that Remplir™ delivers superior nerve regeneration, earlier return to function, and higher quality tissue restoration compared to current surgical suture techniques.
During his visit to Australia, Dr. Ian Valerio discussed the significant global opportunity for Remplir™ following recent FDA approval.
Orthocell has reached a critical milestone in the commercialization of Remplir™ in the US$1.6 Billion US market, recording its first sales revenue from the nerve repair product in the US.
Orthocell has released its Quarterly Report for the period ended 30 June 2025.
Orthocell announced a record quarterly revenue of $2.73 million for the June quarter, marking the fifth consecutive quarter of record revenue growth.
Orthocell recorded the first use of Remplir™ in the US, an important step in establishing surgical experience and knowledge of the product.
Orthocell announced interim results from a study showing that Remplir™ delivers superior nerve regeneration, earlier return to function, and higher quality tissue restoration compared to current surgical suture techniques.
During his visit to Australia, Dr. Ian Valerio discussed the significant global opportunity for Remplir™ following recent FDA approval.